- Home
- CMC vs ALKS Comparison
CMC vs ALKS Comparison
Compare CMC & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMC
- ALKS
- Stock Information
- Founded
- CMC 1915
- ALKS 1987
- Country
- CMC United States
- ALKS Ireland
- Employees
- CMC N/A
- ALKS N/A
- Industry
- CMC Steel/Iron Ore
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- CMC Industrials
- ALKS Health Care
- Exchange
- CMC Nasdaq
- ALKS Nasdaq
- Market Cap
- CMC 5.5B
- ALKS 5.1B
- IPO Year
- CMC 1987
- ALKS 1991
- Fundamental
- Price
- CMC $52.24
- ALKS $27.13
- Analyst Decision
- CMC Buy
- ALKS Strong Buy
- Analyst Count
- CMC 7
- ALKS 13
- Target Price
- CMC $58.75
- ALKS $40.23
- AVG Volume (30 Days)
- CMC 849.7K
- ALKS 2.1M
- Earning Date
- CMC 06-23-2025
- ALKS 07-29-2025
- Dividend Yield
- CMC 1.37%
- ALKS N/A
- EPS Growth
- CMC N/A
- ALKS 21.99
- EPS
- CMC 0.32
- ALKS 2.08
- Revenue
- CMC $7,680,111,000.00
- ALKS $1,505,296,000.00
- Revenue This Year
- CMC N/A
- ALKS N/A
- Revenue Next Year
- CMC $8.04
- ALKS $3.33
- P/E Ratio
- CMC $166.28
- ALKS $12.99
- Revenue Growth
- CMC N/A
- ALKS N/A
- 52 Week Low
- CMC $37.92
- ALKS $25.56
- 52 Week High
- CMC $64.53
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- CMC 52.05
- ALKS 37.44
- Support Level
- CMC $51.40
- ALKS $25.72
- Resistance Level
- CMC $54.54
- ALKS $27.29
- Average True Range (ATR)
- CMC 1.14
- ALKS 0.96
- MACD
- CMC -0.17
- ALKS -0.18
- Stochastic Oscillator
- CMC 40.02
- ALKS 23.00
About CMC Commercial Metals Company
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.